Research programme: 1C metabolism pathway modulators - Raze Therapeutics

Drug Profile

Research programme: 1C metabolism pathway modulators - Raze Therapeutics

Latest Information Update: 12 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Raze Therapeutics
  • Class
  • Mechanism of Action Methylenetetrahydrofolate reductase modulators; Mitochondrial 1C metabolism modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 16 Apr 2016 Pharmaco-dynamics data from an in-vitro study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 14 Oct 2014 Early research in Haematological malignancies in USA (unspecified route)
  • 14 Oct 2014 Early research in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top